Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial
Farid Boulad(Memorial Sloan Kettering Cancer Center), Aurelio Maggio(Ospedale Vincenzo Cervello), Xiuyan Wang(Memorial Sloan Kettering Cancer Center), Paolo Moi(Ospedale Microcitemico), Santina Acuto(Ospedale Vincenzo Cervello), Friederike Kogel(Memorial Sloan Kettering Cancer Center), Chayamon Takpradit(Siriraj Hospital), Susan E. Prockop(Memorial Sloan Kettering Cancer Center), Jorge Mansilla‐Soto(Memorial Sloan Kettering Cancer Center), Annalisa Cabriolu(Memorial Sloan Kettering Cancer Center), Ashlesha Odak(Memorial Sloan Kettering Cancer Center), Jinrong Qu(Memorial Sloan Kettering Cancer Center), Keyur Thummar(Memorial Sloan Kettering Cancer Center), Fang Du(Memorial Sloan Kettering Cancer Center), Lingbo Shen(Memorial Sloan Kettering Cancer Center), Simona Raso(Ospedale Vincenzo Cervello), Rita Barone(Ospedale Vincenzo Cervello), Rosario Di Maggio(Ospedale Vincenzo Cervello), Lorella Pitrolo(Ospedale Vincenzo Cervello), Antonino Giambona(Ospedale Vincenzo Cervello), Maura Mingoia(Ospedale Microcitemico), J.K. Everett(University of Pennsylvania), Pascha Hokama(University of Pennsylvania), Aoife M. Roche(University of Pennsylvania), Adrian Cantu(University of Pennsylvania), Hriju Adhikari(University of Pennsylvania), Shantan Reddy(University of Pennsylvania), Eric E. Bouhassira(Albert Einstein College of Medicine), Narla Mohandas(New York Blood Center), Frederic D. Bushman(University of Pennsylvania), Isabelle Rivière(Memorial Sloan Kettering Cancer Center), Michel Sadelain(Memorial Sloan Kettering Cancer Center)
Cited by 47Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis